Thursday | 20 November, 2008
Stories about: Giaconda
- +
Giaconda begins hep C trial 27/06/2007 15:33:33
Combination therapy trial for refractory hep C begins. - +
Giaconda touts results for H. Pylori, Crohn's disease 31/01/2006 14:50:58
Sydney-based Giaconda (ASX:GIA) has reported positive results from phase II trials of two of its compounds, Heliconda for Helicobacter pylori infection and Myoconda for Crohn's disease. - +
Promising opening for Giaconda 28/09/2005 14:00:00
Sydney-based gastrointestinal drug development company Giaconda (ASX:GIA) has listed today on the Australian Stock Exchange at AUD$0.585, eight cents above its issue price of $0.50. - +
Giaconda aims for Sept IPO 17/08/2005 14:55:54
Sydney-based gastrointestinal drug development company Giaconda, has opened its initial public offering and plans to list on the ASX in late September, with the aim of raising AUD$6 million.
Additional Resources
Newsletter Subscription
Australian Life Scientist Member Login
Kingston Technology Launches HyperX T1 Series Memory 2008-11-19 11:00:00+11
Erase your discs with Lite-On SmartErase 2008-11-12 14:00:00+11
Antarctica NZ to Optimise Satellite Communications over the WAN with Expand Networks 2008-11-11 08:22:00+11
Kingston Technology Launches HyperX DDR3 2GHz Triple-Channel Memory in Support of Intel Core i7, X58 Platforms 2008-11-06 16:40:00+11
WD TV™ HD Media Player brings Digital Media Collections to the Big Screen 2008-11-05 11:00:00+11
Sponsored Links
Subscribe to Australian Life Scientist
Australian Life Scientist is Australia's leading magazine for the life sciences sector.
